Biomarker Classification for Early Lung Disease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing lung diseases, particularly non-small cell lung cancer and reactive airway diseases, lack accuracy and reliability, often requiring physical symptoms to appear before diagnosis, and there is no effective blood test available for early detection.
Innovation Solution
The use of biomarker measurement and classification systems, such as support vector machines, to evaluate physiological samples and classify them based on biomarker measures, enabling early detection and differentiation between lung diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If current diagnostic methods (X-rays, CT scans, spirometry) are used to detect lung diseases, then physical symptoms must be present for diagnosis, but early detection before symptom appearance is not achieved
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels in blood samples before clinical symptoms appear. The methodology enables detection of lung cancer and reactive airway diseases at pre-symptomatic stages by analyzing biomarker profiles that change before physical manifestations occur, thus performing the diagnostic action in advance of traditional symptom-based detection
Solution Approach 2:
The patent replaces mechanical/physical diagnostic systems (X-rays, CT scans, spirometry) with a biochemical detection system based on biomarker measurement. Instead of using imaging technology or lung function tests that require physical symptoms, the invention uses blood-based biomarker analysis to detect disease presence through molecular indicators, substituting one diagnostic paradigm for another
2Reliability
If multiple tests are performed to rule out other pathologies, then diagnostic coverage is comprehensive, but test complexity and time increase
Solution Approach 1:
The patent merges multiple diagnostic functions into a single integrated biomarker measurement system. By measuring a panel of biomarkers simultaneously in one blood test, the invention combines what would traditionally require multiple separate tests (cancer screening, asthma detection, COPD evaluation) into a unified diagnostic approach, reducing test complexity while maintaining comprehensive coverage
Solution Approach 2:
The patent creates a universal diagnostic system that can detect multiple different lung pathologies (lung cancer, asthma, COPD, pneumonia) through a single biomarker measurement platform. The same blood test and analysis methodology serves multiple diagnostic purposes, making the system multi-functional and reducing the need for disease-specific tests
3Measurement precision
If classification systems are used to analyze biomarker data, then diagnostic accuracy improves to over 90%, but system complexity increases
Solution Approach 1:
The patent introduces a classification system as an intermediary between raw biomarker measurements and diagnostic conclusions. The system processes biomarker level data through algorithms that compare measurements against established thresholds and patterns, acting as a mediator that translates complex biochemical data into clear diagnostic decisions, thereby improving accuracy while managing complexity through systematic processing
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. Measurements of these biomarkers are inputted into a classification system such as a support vector machine or AdaBoost to assist in determining the likelihood that an individual has a lung disease. Kits comprising agents for detecting the biormarkers and combination of biormarkers, as well as systems that assist in diagnosing lung diseases are also provided.